blood cancer
Genmab’s CLL drug gets negative opinion from EMA committee
June 24, 2016Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer
Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
Nice rejects Celgene’s drug to treat blood cancer
June 24, 2016Medical Communications, Research and Development CDF, Celgene, NICE, Vidaza, blood cancer
The National Institute for Health and Care Excellence (Nice) rejected biotech firm Celgene’s (Nasdaq: CELG) Vidaza (azacitidine) to treat a …
Janssen says Imbruvica shows improved PFS in blood cancer in long-term effectiveness study
June 14, 2016Manufacturing and Production, Research and Development Janssen, blood cancer, drug trial, imbruvica
Janssen said late-stage studies to test long-term effectiveness for its Imbruvica (ibrutinib) in blood cancer showed improved progression free survival …
EMA starts review of Gilead Sciences’ Zydelig following safety concerns
March 14, 2016Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig
Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
Roche falls foul of NICE rules, again
October 3, 2014Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology
Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …
Gilead’s blood cancer pill approved in Europe
September 22, 2014Sales and Marketing CLL, Gilead, blood cancer, fl, idelalisib, oncology, zydelig
Gilead has gained European Commission approval for its new blood cancer pill Zydelig (idelalisib) as it looks to expand further …
AbbVie and Infinity sign cancer deal
September 4, 2014Research and Development, Sales and Marketing AbbVie, IPI-145, blood cancer, duvelisib, infinity
AbbVie has partnered with US company Infinity Pharmaceuticals to develop and commercialise the latter firm’s blood cancer treatment duvelisib (IPI-145). …
EMA gets first line Arzerra submission
October 7, 2013Sales and Marketing Arzerra, GSK, Genmab, blood cancer
GlaxoSmithKline and Genmab have submitted their blood cancer drug Arzerra to the European Medicines Agency (EMA) in a first line …
Ariad files new blood cancer drug with the FDA
July 31, 2012Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer
Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …
Blood cancer charity to kick-start clinical trials
May 19, 2011Research and Development Cancer, blood cancer, clinical trials, leukaemia
A UK blood cancer charity is creating a network of clinical trial centres with backing from the NIHR Clinical Research …
Novartis plans Q2 filing for blood cancer drug
March 17, 2011Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib
Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
Novartis blood cancer drug impresses in late stage trial
December 22, 2010Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug
Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
Roche’s MabThera successor shows phase II promise
December 6, 2010Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia
The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …
Pfizer withdraws blood cancer drug in US
June 22, 2010Sales and Marketing AML, Mylotarg, Pfizer, blood cancer
The US regulatory body has withdrawn Pfizer’s leukaemia drug Mylotarg after it was linked to a number of deaths, and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
